DOCSLIB.ORG

Form-‐Based Case Report

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Form-‐Based Case Report Form-Based Case Report Name: Pam Satjawatcharaphong Email: [email protected] Address: 200 Minor Hall, Berkeley, CA 94720 Case Report #: 1 of 2 Management of Exposure Keratopathy Secondary to Facial Nerve Palsy with a Scleral Gas Permeable Contact Lens Introduction Facial nerve palsy is a disorder of cranial nerve VII that controls movement of the muscles in the face. Damage to this nerve typically results in unilateral facial weakness or paralysis. Patients may experience drooping of one side of the face, drooling, dry mouth, loss of sense of taste, inability to close the affected eye, and twitching of the facial muscles. Ocular sequelae of this condition include ptosis, lagophthalmos, exposure keratopathy, epiphora, ulceration of the cornea, and decreased vision.1 Recommended treatment of this condition has been dependent on the nature of the corneal exposure, and includes options ranging from palliative lubricants to surgical lid procedures. Taking into account the considerable risk of complications with medical and surgical modes of management, scleral GP contact lenses present a less invasive and very effective way to treat patients suffering from the symptoms of paralytic lagophthalmos and exposure keratopathy. 1 Case Report Patient Demographics & History Patient initials: JC Patient age, race, and gender: 50 year old Caucasian female Occupation: Unemployed Personal ocular history: Acoustic neuroma surgery at age 25 resulting in cranial nerve VII damage and permanent right facial paralysis. Gold weights were subsequently implanted in the upper lid. Personal medical history: Acid reflux disease Current medications: Protonix Drug allergies: None Family ocular history: Unremarkable Family medical history: Arthritis, cancer Other notes: N/A Examination Findings Visit # 1 of 6 Date of Examination 8/1/2012 Referral? Yes No Chief Complaint/Purpose of Visit: Constant severe dryness OD Entering vision: Uncorrected Glasses Contact Lenses Other OD -3.75-0.50x008 (VA 20/200) OS -4.75-1.00x145 (VA 20/15) Refraction: OD -3.75-0.50x008 (VA 20/200) OS -4.75-1.00x145 (VA 20/15) Pupils: PERRL (-)APD Extraocular Muscles: Full OU 2 Anterior Segment OD OS Ptosis due to gold weight Lids/Lashes Gr 1+ plugged glands implant, lagophthalmos, Gr 2+ plugged glands Gr 2 hyperemia Bulbar Conjunctiva Unremarkable Unremarkable Palpebral Conjunctiva Unremarkable Gr 1 engorged vessels Sclera Gr 1 engorged vessels Gr 4+ staining and Cornea Gr 1+ arcus keratinization inferiorly (Figure 1), Gr 1+ arcus Deep and quiet Anterior Chamber Deep and quiet Flat, blue Iris Flat, blue Gr 1+ nuclear sclerosis Lens Gr 1+ nuclear sclerosis Figure 1 – Severe staining with sodium fluorescein and Wrattan filter Intraocular Pressure: Goldmann Tonopen NCT Other OD 18 mmHg OS 17 mmHg at 4:07 PM Visual Field: OD Full OS Full Type: Confrontation VF Dilation drops? Yes No 3 Posterior Segment OD OS Distinct margins, choroidal Optic Nerve Distinct margins, choroidal crescent crescent 0.30H/0.30V C/D 0.50H/0.50V Present Foveal Reflex Present Flat, even, avascular Macula Flat, even, avascular Unremarkable Posterior Pole Unremarkable Normal caliber Vasculature Normal caliber Unremarkable Periphery Unremarkable Unremarkable Vitreous Unremarkable Additional Testing Figure 2 - Medmont Corneal Topography Showing Irregular Astigmatism OD and Regular With-the-rule Astigmatism OS 4 Assessment: 1. Exposure keratopathy OD 2. Irregular astigmatism secondary to corneal keratinization OD (Figure 2) 3. Glaucoma suspect based on asymmetric C/D Plan: 1-2. Return in 1 week to initiate scleral lens fitting OD to improve both ocular comfort and vision 3. Refer for glaucoma work-up Contact Lens Fitting Visit # 2 of 6 Date of Examination 8/8/2012 Chief Complaint/Purpose of Visit: Scleral lens fitting Entering Vision: Uncorrected Glasses Contact Lenses Other OD -3.75-0.50x008 (VA 20/200) OS -4.75-1.00x145 (VA 20/15) Anterior Segment Notes: OD No change from visit 1 OS No change from visit 1 Trial Lens Design: Jupiter Standard Scleral Length of time trial lens settled before fit assessment: 30 minutes OD Trial # 1 of 1 OS 41.00 (8.23) Base Curve N/A N/A Sagittal Depth N/A 18.2/8.2 Diameter/OZ N/A -1.50 Power N/A Standard Peripheral Curves N/A Modified: 300 um apical clearance, Fit Description N/A full limbal clearance, trace edge lift at the 3 o’clock and 9 o’clock lens margins, and no blood vessel blanching -7.50 Over-Refraction N/A 20/40 VA N/A 5 Ordered Lens Design: Jupiter Standard Scleral OD Lens Order OS 41.00 (8.23) Base Curve N/A N/A Sagittal Depth N/A 18.2/8.2 Diameter/OZ N/A -4.75 Power N/A Standard Peripheral Curves N/A Modified:Steepen PC4 Boston XO Material N/A Assessment: Ordered first scleral lens OD. Since the patient wanted to continue to wear her current spectacles over the contact lens to protect her eyes, the contact lens power that was ordered was adjusted to compensate for her spectacle lens power. The fourth peripheral curve was steepened slightly due to the edge lift noted with the trial lens. Plan: Return in 2 weeks for scleral lens dispense and training. 6 Visit # 3 of 6 Date of Examination 8/24/12 Chief Complaint/Purpose of Visit: Scleral lens first dispense and training Entering Vision: Uncorrected Glasses Contact Lenses Other OD -3.75-0.50x008 (VA 20/200) OS -4.75-1.00x145 (VA 20/15) Lens Design: Jupiter Standard Scleral OD OS 41.00 (8.23) Base Curve N/A N/A Sagittal Depth N/A 18.2/8.2 Diameter/OZ N/A -4.75 Power N/A Standard Peripheral Curves N/A Modified:Steepen PC4 Boston XO Material N/A 300 um apical clearance, Fit Description N/A full limbal clearance (Figure 3) with no vessel blanching and good scleral alignment (Figures 4a-4d) 20/40+2 VA N/A +0.25 (20/30) Over-Refraction (VA) N/A Anterior Segment Notes: OD No change from visit 2 OS No change from visit 2 Application and Removal Successful? Yes No Dispense Lenses? Yes No Solution Recommended for Cleaning/Disinfection/Storage: Boston Simplus Solution Recommended for Filling Lens: Unisol 4 Additional Instructions to Patient: N/A New Lens Order? Yes No Lens Design: N/A OD Lens Order OS N/A Base Curve. N/A N/A Sagittal Depth N/A N/A Diameter/OZ N/A N/A Power N/A N/A Peripheral Curves N/A N/A Material N/A 7 Figure 3 – Scleral lens filled with sodium fluorescein showing corneal and limbal clearance Figures 4a-4d—Proper alignment of the contact lens with the sclera in all quadrants Assessment: Good initial comfort, fit, and vision with scleral OD. Plan: Dispensed scleral to patient. The patient was instructed on proper cleaning regimen and to allow for an adaptation period when first wearing this lens—starting with 6 hours gradually increasing wear time until full-time wear was achieved. The patient was also told not to sleep in the lens, so in order to continue to provide corneal protection, JC used a lubricating ointment for her right eye before bedtime. Return for 2 week follow-up appointment. 8 Visit # 4 of 6 Date of Examination 9/7/2012 Chief Complaint/Purpose of Visit: 2 week scleral lens follow-up. Patient reports significant subjective improvement in dryness symptoms and vision OD. Entering Vision: Uncorrected Glasses Contact Lenses Other OD Scleral with overlay glasses (VA 20/20-) OS Glasses (VA 20/15) Average Comfortable Wearing Time: 12 hours Wearing Time On Day of Visit: 4 hours Lens Design: Jupiter Standard Scleral OD OS 41.00 (8.23) Base Curve N/A N/A Sagittal Depth N/A 18.2/8.2 Diameter/OZ N/A -4.75 Power N/A Standard Peripheral Curves N/A Modified:Steepen PC4 Boston XO Material N/A 200 um apical clearance, Fit Description N/A full limbal clearance, no vessel blanching and good scleral alignment, some mucus strands on surface 20/20- VA N/A +0.25 (No improvement) Over-Refraction (VA) N/A Anterior Segment Notes: OD Improvement in corneal staining from Gr 4+ to Gr 3. Also improvement in ptosis as scleral acts as crutch for upper lid (Figure 5a-b). Otherwise, no changes from visit 3. OS No change from visit 3 Dispense Lenses? Yes No N/A Additional Instructions to Patient: N/A New Lens Order? Yes No Lens Design: N/A OD Lens Order OS N/A Base Curve. N/A N/A Sagittal Depth N/A N/A Diameter/OZ N/A N/A Power N/A N/A Peripheral Curves N/A N/A Material N/A 9 Figure 5a - Eye without scleral (left) Figure 5b – eye with scleral showing improvement in ptosis (right) Assessment: Improved vision and comfort with scleral lens OD. Plan: Continue with current OD lens, and discussed with patient that improvement in vision likely due to improved corneal staining. Patient can use rewetting drops over scleral or remove lens to clean as needed. Patient should continue to use ointment at night. Return in 2 months for progress check. 10 Visit # 5 of 6 Date of Examination 11/9/2012 Chief Complaint/Purpose of Visit: 2 month scleral lens progress check. Patient reports continued good comfort and vision. Entering Vision: Uncorrected Glasses Contact Lenses Other OD Scleral with overlay glasses (VA 20/20-) OS Glasses (VA 20/15) Average Comfortable Wearing Time: 12 hours Wearing Time On Day of Visit: 6 hours Lens Design: Jupiter Standard Scleral OD OS OS 41.00 (8.23) Base Curve N/A N/A Sagittal Depth N/A 18.2/8.2 Diameter/OZ N/A -4.75 Power N/A Standard Peripheral Curves N/A Modified:Steepen PC4 Boston XO Material N/A 200 um apical clearance, Fit Description N/A full limbal clearance, good scleral alignment except some mild blanching over shallow temporal pinguecula 20/20- VA N/A Plano (No improvement) Over-Refraction (VA) N/A Anterior Segment Notes: OD Improvement in corneal staining from Gr 3 to Gr 2 (Figure 6), otherwise no change from visit 4 OS No change from visit 4 Dispense Lenses? Yes No N/A Additional Instructions to Patient: N/A New Lens Order? Yes No Lens Design: N/A OD Lens Order OS N/A Base Curve.
Load more

Recommended publications
  • In Vivo Confocal Microscopy of Toxic Keratopathy
    Eye (2017) 31, 140–147 OPEN Official journal of The Royal College of Ophthalmologists www.nature.com/eye CLINICAL STUDY In vivo confocal Y Chen, Q Le, J Hong, L Gong and J Xu microscopy of toxic keratopathy Abstract Purpose To explore the morphological although a wide variety of chemicals and characteristics of toxic keratopathy (TK), systemic medications can also cause TK.1 Cases which clinically presented as superficial of drug-induced TK have been prevalent in punctate keratopathy (SPK), with the ophthalmic clinics for two reasons. On the one application of in vivo laser-scanning confocal hand, most of the topically applied drugs, either microscopy (LSCM), and evaluate its potential prescribed or sold over-the-counter, are capable in the early diagnosis of TK. of causing corneal damage at sufficient Patients and methods This was a cross- concentrations.2 Patients who have glaucoma, sectional study involving 16 patients with viral keratitis, keratoconjunctivitis sicca or other TK and 16 patients with dry eye (DE), ocular surface conditions, generally need demonstrating SPK under slit-lamp multidrug remedies, and these pre-existing observation, and 10 normal eyes were conditions may especially predispose them to enrolled in the study. All participants drug toxicity. The preservative in the eye drops, underwent history interviews, fluorescein mainly benzalkonium chloride (BAC), is another staining, tear film break-up time (BUT) tests, important cause for epithelial lesions. On the Schirmer tests, and in vivo LSCM. other hand, the use of eye drops for a week or Results The area grading of corneal more may cause TK, which can often be confused fluorescein punctate staining was higher in with the worsening of the patient’s initial disease the TK group than the DE group.
    [Show full text]
  • Refractive Surgery Faqs. Refractive Surgery the OD's Role in Refractive
    9/18/2013 Refractive Surgery Refractive Surgery FAQs. Help your doctor with refractive surgery patient education Corneal Intraocular Bill Tullo, OD, FAAO, LASIK Phakic IOL Verisys Diplomate Surface Ablation Vice-President of Visian PRK Clinical Services LASEK CLE – Clear Lens Extraction TLC Laser Eye Centers Epi-LASIK Cataract Surgery AK - Femto Toric IOL Multifocal IOL ICRS - Intacs Accommodative IOL Femtosecond Assisted Inlays Kamra The OD’s role in Refractive Surgery Refractive Error Determine the patient’s interest Myopia Make the patient aware of your ability to co-manage surgery Astigmatism Discuss advancements in the field Hyperopia Outline expectations Presbyopia/monovision Presbyopia Enhancements Risks Make a recommendation Manage post-op care and expectations Myopia Myopic Astigmatism FDA Approval Common Use FDA Approval Common Use LASIK: 1D – 14D LASIK: 1D – 8D LASIK: -0.25D – -6D LASIK: -0.25D – -3.50D PRK: 1D – 13D PRK: 1D – 6D PRK: -0.25D – -6D PRK: -0.25D – -3.50D Intacs: 1D- 3D Intacs: 1D- 3D Intacs NONE Intacs: NONE P-IOL: 3D- 20D P-IOL: 8D- 20D P-IOL: NONE P-IOL: NONE CLE/CAT: any CLE/CAT: any CLE/CAT: -0.75D - -3D CLE/CAT: -0.75D - -3D 1 9/18/2013 Hyperopia Hyperopic Astigmatism FDA Approval Common Use FDA Approval Common Use LASIK: 0.25D – 6D LASIK: 0.25D – 4D LASIK: 0.25D – 6D LASIK: 0.25D – 4D PRK: 0.25D – 6D PRK: 0.25D – 4D PRK: 0.25D – 6D PRK: 0.25D – 4D Intacs: NONE Intacs: NONE Intacs: NONE Intacs: NONE P-IOL: NONE P-IOL: NONE P-IOL: NONE P-IOL:
    [Show full text]
  • Posterior Cornea and Thickness Changes After Scleral Lens Wear in Keratoconus Patients
    Contact Lens and Anterior Eye xxx (xxxx) xxx–xxx Contents lists available at ScienceDirect Contact Lens and Anterior Eye journal homepage: www.elsevier.com/locate/clae Posterior cornea and thickness changes after scleral lens wear in keratoconus patients Maria Serramitoa, Carlos Carpena-Torresa, Jesús Carballoa, David Piñerob,c, Michael Lipsond, ⁎ Gonzalo Carracedoa,e, a Department of Optics II (Optometry and Vision), Faculty of Optics and Optometry, Universidad Complutense de Madrid, Madrid, Spain b Group of Optics and Visual Perception, Department of Optics, Pharmacology and Anatomy, University of Alicante, Spain c Department of Ophthalmology (OFTALMAR), Vithas Medimar International Hospital, Alicante, Spain d Department of Ophthalmology and Visual Science, University of Michigan, Northville, MI, USA e Ocupharm Group Research, Department of Biochemistry and Molecular Biology IV, Faculty of Optics and Optometry, Universidad Complutense de Madrid, Madrid, Spain ARTICLE INFO ABSTRACT Keywords: Purpose: To evaluate the changes in the corneal thickness, anterior chamber depth and posterior corneal cur- Scleral lenses vature and aberrations after scleral lens wear in keratoconus patients with and without intrastromal corneal ring Keratoconus segments (ICRS). Corneal curvature Methods: Twenty-six keratoconus subjects (36.95 ± 8.95 years) were evaluated after 8 h of scleral lens wear. Corneal aberrations The subjects were divided into two groups: those with ICRS (ICRS group) and without ICRS (KC group). The Anterior chamber study variables evaluated before and immediately after scleral lens wear included corneal thickness evaluated in Corneal thickness different quadrants, posterior corneal curvature at 2, 4, 6 and 8 mm of corneal diameter, posterior corneal aberrations for 4, 6 and 8 mm of pupil size and anterior chamber depth.
    [Show full text]
  • Diagnosis and Treatment of Neurotrophic Keratopathy
    An Evidence-based Approach to the Diagnosis and Treatment of Neurotrophic Keratopathy ACTIVITY DIRECTOR A CME MONOGRAPH Esen K. Akpek, MD This monograph was published by Johns Hopkins School of Medicine in partnership Wilmer Eye Institute with Catalyst Medical Education, LLC. It is Johns Hopkins School of Medicine not affiliated with JAMA medical research Baltimore, Maryland publishing. Visit catalystmeded.com/NK for online testing to earn your CME credit. FACULTY Natalie Afshari, MD Mina Massaro-Giordano, MD Shiley Eye Institute University of Pennsylvania School of Medicine University of California, San Diego Philadelphia, Pennsylvania La Jolla, California Nakul Shekhawat, MD, MPH Sumayya Ahmad, MD Wilmer Eye Institute Mount Sinai School of Medicine Johns Hopkins School of Medicine New York, New York Baltimore, Maryland Pedram Hamrah, MD, FRCS, FARVO Christopher E. Starr, MD Tufts University School of Medicine Weill Cornell Medical College Boston, Massachusetts New York, New York ACTIVITY DIRECTOR FACULTY Esen K. Akpek, MD Natalie Afshari, MD Mina Massaro-Giordano, MD Professor of Ophthalmology Professor of Ophthalmology Professor of Clinical Ophthalmology Director, Ocular Surface Diseases Chief of Cornea and Refractive Surgery University of Pennsylvania School and Dry Eye Clinic Vice Chair of Education of Medicine Wilmer Eye Institute Fellowship Program Director of Cornea Philadelphia, Pennsylvania Johns Hopkins School of Medicine and Refractive Surgery Baltimore, Maryland Shiley Eye Institute Nakul Shekhawat, MD, MPH University of California,
    [Show full text]
  • Medical Policy Gas Permeable Scleral Contact Lens
    Medical Policy Gas Permeable Scleral Contact Lens Table of Contents Policy: Commercial Coding Information Information Pertaining to All Policies Policy: Medicare Description References Authorization Information Policy History Policy Number: 371 BCBSA Reference Number: 9.03.25 Related Policies Corneal Topography/Computer-Assisted Corneal Topography/Photokeratoscopy, #301 Implantation of Intrastromal Corneal Ring Segments, #235 Policy Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity Medicare HMO BlueSM and Medicare PPO BlueSM Members Rigid gas permeable scleral lens may be considered MEDICALLY NECESSARY for patients who have not responded to topical medications or standard spectacle or contact lens fitting, for the following conditions: Corneal ectatic disorders (e.g., keratoconus, keratoglubus, pellucid marginal degeneration, Terrien’s marginal degeneration, Fuchs’ superficial marginal keratitis, post-surgical ectasia); Corneal scarring and/or vascularization; Irregular corneal astigmatism (e.g., after keratoplasty or other corneal surgery); Ocular surface disease (e.g., severe dry eye, persistent epithelial defects, neurotrophic keratopathy, exposure keratopathy, graft vs. host disease, sequelae of Stevens Johnson syndrome, mucus membrane pemphigoid, post-ocular surface tumor excision, post-glaucoma filtering surgery) with pain and/or decreased visual acuity. Prior Authorization Information Commercial Members: Managed Care (HMO and POS) Prior authorization is NOT required. Commercial Members: PPO, and Indemnity
    [Show full text]
  • Eye Care in the Intensive Care Unit (ICU)
    Ophthalmic Services Guidance Eye Care in the Intensive Care Unit (ICU) June 2017 18 Stephenson Way, London, NW1 2HD T. 020 7935 0702 [email protected] rcophth.ac.uk @RCOphth © The Royal College of Ophthalmologists 2017 All rights reserved For permission to reproduce any of the content contained herein please contact [email protected] Contents Section page 1 Summary 3 2 Introduction 3 Protecting the eye of the vulnerable patient 4 3 Identifying disease of the eye 6 Exposure keratopathy and corneal abrasion 6 Chemosis 8 Microbial infections 8 4 Rare eye conditions in ICU 10 Red eye in a septic patient: possible endogenous endophthalmitis 10 Other problems 11 5 Delivering treatment to the eye when it is prescribed 11 Red eye in ICU patient 12 6. Systemic fungal infection and the eye for intensivists 14 7. Tips for ophthalmologists seeing patients in ICU 14 8. Authors 16 9. References 17 Date of review: July 2020 2017/PROF/350 2 1 Summary This document aims to provide advice and information for clinical staff who are involved in eye care in the ICU. It is primarily intended to help non-ophthalmic ICU staff to: 1. protect the eye in vulnerable patients, thus preventing ICU-related eye problems 2. identify disease affecting the eye in ITU patients, and specifically those which might need ophthalmic referral 3. deliver treatment to the eye when it is prescribed It concentrates primarily on the common problems of the eye surface but also touches on other less common conditions. As such, it should also be helpful to those ophthalmologists asked for advice about ICU patients.
    [Show full text]
  • Toxic Keratopathy Following the Use of Alcohol-Containing Antiseptics in Nonocular Surgery
    Research Brief Report Toxic Keratopathy Following the Use of Alcohol-Containing Antiseptics in Nonocular Surgery Hsin-Yu Liu, MD; Po-Ting Yeh, MD; Kuan-Ting Kuo, MD; Jen-Yu Huang, MD; Chang-Ping Lin, MD; Yu-Chih Hou, MD IMPORTANCE Corneal abrasion is the most common ocular complication associated with nonocular surgery, but toxic keratopathy is rare. OBSERVATION Three patients developed severe toxic keratopathy after orofacial surgery on the left side with general anesthesia. All patients underwent surgery in the right lateral tilt position with ocular protection but reported irritation and redness in their right eyes after the operation. Alcohol-containing antiseptic solutions were used for presurgical preparation. Ophthalmic examination showed decreased visual acuity ranging from 20/100 to 20/400, corneal edema and opacity, anterior chamber reaction, or stromal neovascularization in the patients’ right eyes. Confocal microscopy showed moderate to severe loss of corneal endothelial cells in all patients. Despite prompt treatment with topical corticosteroids, these Author Affiliations: Department of Ophthalmology, National Taiwan 3 patients eventually required cataract surgery, endothelial keratoplasty, or penetrating University Hospital, College of keratoplasty, respectively. After the operation, the patients’ visual acuity improved to 20/30 Medicine, National Taiwan University, or 20/40. Data analysis was conducted from December 6, 2010, to June 15, 2015. Taipei, Taiwan (Liu, Yeh, Huang, Lin, Hou); Department of Pathology, National Taiwan University Hospital, CONCLUSIONS AND RELEVANCE Alcohol-containing antiseptic solutions may cause severe College of Medicine, National Taiwan toxic keratopathy; this possibility should be considered in orofacial surgery management. University, Taipei, Taiwan (Kuo). Using alcohol-free antiseptic solutions in the periocular region and taking measures to protect Corresponding Author: Yu-Chih the dependent eye in the lateral tilt position may reduce the risk of severe corneal injury.
    [Show full text]
  • Refractive Management/Intervention 2017-2019
    Academy MOC Essentials® Practicing Ophthalmologists Curriculum 2017–2019 Refractive Management/Intervention *** Refractive Management/Intervention 2 © AAO 2017-2019 Practicing Ophthalmologists Curriculum Disclaimer and Limitation of Liability As a service to its members and American Board of Ophthalmology (ABO) diplomates, the American Academy of Ophthalmology has developed the Practicing Ophthalmologists Curriculum (POC) as a tool for members to prepare for the Maintenance of Certification (MOC) -related examinations. The Academy provides this material for educational purposes only. The POC should not be deemed inclusive of all proper methods of care or exclusive of other methods of care reasonably directed at obtaining the best results. The physician must make the ultimate judgment about the propriety of the care of a particular patient in light of all the circumstances presented by that patient. The Academy specifically disclaims any and all liability for injury or other damages of any kind, from negligence or otherwise, for any and all claims that may arise out of the use of any information contained herein. References to certain drugs, instruments, and other products in the POC are made for illustrative purposes only and are not intended to constitute an endorsement of such. Such material may include information on applications that are not considered community standard, that reflect indications not included in approved FDA labeling, or that are approved for use only in restricted research settings. The FDA has stated that it is the responsibility of the physician to determine the FDA status of each drug or device he or she wishes to use, and to use them with appropriate patient consent in compliance with applicable law.
    [Show full text]
  • Overflow Tearing in Infants
    The Tearing Patient: Diagnosis and Management Written By: Kristina M. Price, MD, and Michael J. Richard, MD Edited by Ingrid U. Scott, MD, MPH, and Sharon Fekrat, MD Excessive tearing, also known as epiphora, is due to a disruption in the balance between tear production and tear loss. Numerous etiologies lead to an excess of tears, and there are a number of ways to diagnose and treat this condition. Currently, there is not a firm consensus on the best way to evaluate the tearing patient. However, a simple algorithm may aid the general ophthalmologist in the evaluation and management of this common condition. Anatomy and Physiology of the Lacrimal System The main lacrimal gland, the accessory lacrimal glands and the conjunctival epithelium are responsible for producing tears. Tears are spread over the surface of the eye by blinking to establish the precorneal tear film. Each contraction of the orbicularis muscle helps move the tears across the ocular surface toward the lacrimal drainage system. Ideally, the basal tear secretion rate equals the rate of tear drainage and evaporation. Basal tear secretion occurs at a rate of about 1.2 µl/minute, although reflexive tear secretion can increase this up to 100-fold. Tears enter the puncta at a rate of 0.6 µl/min; about 90 percent are reabsorbed through the nasolacrimal duct mucosa and 10 percent drain into the floor of the nasal cavity. Tears evaporate from the ocular surface at a variable rate, but ideally tear evaporation roughly equals the difference between basal secretion and drainage. The ocular surface (including the lacrimal lakes in the conjunctival fornices, the marginal tear strip and the precorneal tear film) can hold only 8 µl of tears at any time.
    [Show full text]
  • Dr. Bozung, Not Your Average Dry
    9/11/2019 Not Your Average Dry Eye WHAT IS DRY EYE? Alison Bozung, OD, FAAO Bascom Palmer Eye Institute 1 2 Dry Eye Dry Eye • TFOS DEWS II, 2017 • Symptoms – “A multifactorial disease of the ocular surface characterized by a loss of homeostasis of the tear film, and accompanied by ocular – Redness, burning, blurred vision, pain, tearing symptoms, in which tear film instability and hyperosmolarity, ocular surface inflammation and damage, and neurosensory abnormalities play etiological roles.” • Prevalence – Anywhere from 5-50% of individuals have symptoms of dry eye (TFOS DEWS II) Thinkaboutyoureyes.com, https://medicaldialogues.in/new-delhi-20-people-develop-blur-vision-after-being-given-contaminated-avastin-injection/, https://www.lasikmd.com/blog/the-risks- that-come-with-rubbing-your-eyes, https://www.powerofpositivity.com/10-things-that-cause-eye-pain/ 3 4 Dry Eye Dry Eye • Signs 1. Aqueous Deficient (ADDE) • Conjunctival injection, meibomian gland dysfunction, corneal and conjunctival staining, reduced tear prism, rapid tear break up, 2. Evaporative (EDE) corneal scarring and thinning 3. Mixed Does that explain everything..? https://www.eyedolatryblog.com/2011/12/patients-guide-to-dry-eye-syndrome_15.html, https://www.pharmaceutical-journal.com/eye-care/pharmacy-technicians-guide-blepharitis- managing-eyelid-inflammation/20203771.article?firstPass=false, 5 6 1 9/11/2019 Beyond your “Typical” Dry Eye • Today’s Discussion: 1. Exposure Keratopathy 2. Ocular Graft Versus Host Disease 3. Neurotrophic Keratopathy Craig JP et al. TFOS DEWS II report executive summary. Ocul Surf. 2017;15:802-812. 7 8 What defines exposure keratopathy? • Desiccation of the cornea occurring from inadequate eyelid closure or decreased blink frequency.
    [Show full text]
  • Scleral Lenses to the Rescue in the Management of Ocular Surface
    SCLERAL LENSES TO THE RESCUE IN THE Lindsay B. Howse, OD MANAGEMENT OF OCULAR SURFACE [email protected] DISEASE FINANCIAL DISCLOSURES None. OUTLINE •Overview of OSD & Dry eye • Definition • Types of OSD • Current OSD management options •Role of Scleral CLs in managing OSD • Benefits • Case examples • Short-term effects • Long-term effects •Fundamentals of Scleral CL fitting • Tips and tricks for an ideal fit OSD is “clinical damage to the intrapalpebral ocular surface or symptoms of such disruption for a variety of causes”. (AOA Optometric Clinical Practical Guidelines) WHAT IS OCULAR SURFACE DISEASE? Report of the International Dry Eye WorkShop 2007 “Dry eye is a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance and tear film instability with potential damage to the ocular surface. It is accompanied by increased osmolarity of the tear film and inflammation of the ocular surface”. (International Dry Eye Workshop 2007) WHAT IS DRY EYE DISEASE? Report of the International Dry Eye WorkShop 2007 TOOLS FOR MANAGING OSD/DRY EYE •Mild/Moderate Disease: • Environmental modifications • Artificial tears • Hot compresses • Omega-3 supplementation • Punctal plugs/punctal cautery • Steroids • Cyclosporine A • Lifitegrast • Tetracyclines •Severe Disease: • Autologous serum tears • Bandage soft contact lenses • Amniotic membranes • Surgical intervention (Tarsorrhaphy) • Scleral Contact Lenses http://www.boringchoreshandyman.com.au/portfolio/boring-chores-handyman-10/ SCLERAL LENSES
    [Show full text]
  • Exposure Keratopathy After Cosmetic CO2 Laser Skin Resurfacing
    Cornea 19(6): 846–848, 2000. © 2000 Lippincott Williams & Wilkins, Inc., Philadelphia Exposure Keratopathy After Cosmetic CO2 Laser Skin Resurfacing Anita I. Miedziak, M.D., John D. Gottsch, M.D., and Nicholas T. Iliff, M.D. Purpose. To report two cases of exposure keratopathy after cos- had also a full face lift with bilateral lower lid blepharoplasty 25 metic CO2 laser skin resurfacing. Methods. Two patients pre- years before this evaluation. Patient’s past and present medical sented with bilateral intrapalpebral epitheliopathy. They were ex- history was negative. Her best corrected visual acuity was 20/20 amined, treated, and followed for several weeks. Results. Nonsur- OD and 20/30 OS. Her external examination revealed a 3-mm gical treatment options, including a variety of lubricants, punctal bilateral lower lid retraction, mild bilateral ptosis (Fig. 1A), and a plugs, and lid taping, did not lead to a complete resolution of 1-mm lagophthalmos OU. There was a mild, bilateral lower lid symptoms. Surgical options were recommended. Conclusion. Ex- posure keratopathy should be recognized as a potential side effect laxity noted (tested by distraction test) with slight left lower punc- tal ectropion. Otherwise lid approximation to the globe was good of not only incisional lid surgery but also facial CO2 laser skin resurfacing procedures. OU. Pupillary and visual field examinations were normal. Con- Key Words: Exposure keratopathy—CO2 laser skin resurfacing— junctivae were 2+ injected OD and 1+ OS. Corneas manifested Cosmetic lid surgery—Iatrogenic keratopathy—Lower lid retrac- intrapalpebral punctate epitheliopathy that was more prominent in tion. the right eye (Fig.
    [Show full text]